Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through year one in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Ocrevus, and what are their perceptions of this product?
  • For which patients are neurologists prescribing Ocrevus, what are their reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What are the promotional messages and activities that Genentech and Roche are employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare with other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product description:

Launch Tracking: Ocrevus Wave 1 (US) Relapsing Forms of Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Ocrevus Relapsing Forms Of Multiple Sclerosis - Wave 1 (US)
    • Key Findings
      • Benchmarking Ocrevus's Launch Success vs. the Competition
        • One Month Postlaunch, Ocrevus Appears to Be in a Strong Competitive Position
        • Benchmarking Ocrevus's Launch Success vs. Other Launched Drugs
      • Prescriber and Nonprescriber Profiles
        • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
        • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Awareness and Perceptions
        • Unaided and Aided Awareness of Ocrevus
          • Unaided Awareness of Ocrevus Is Substantial One Month Postlaunch
          • Unaided Awareness of Drugs Approved or Launched for the Treatment of MS
          • Aided Awareness of Ocrevus
          • Aided Awareness of the Comparator Used in Ocrevus's Pivotal Clinical Trials in Relapsing Forms of MS
          • Aided Awareness of Ocrevus's Indication
          • Aided Awareness of Ocrevus's Mechanism of Action and Route of Administration
          • Aided Awareness of Ocrevus's Dosing Interval
          • Aided Awareness of Ocrevus's Clinical Profile in Relapsing Forms of MS
        • Familiarity with Ocrevus
          • Nearly All Respondents Reported Moderate to High Familiarity with Ocrevus
          • Level of Familiarity with Ocrevus
        • Sources of Familiarity with Ocrevus
          • Sources of Familiarity with Ocrevus at One Month Postlaunch Have Been Academic in Nature
        • Initial Reaction to and Interest in Ocrevus
          • Surveyed Neurologists' Initial Reaction to Ocrevus is Favorable and Interest Level Is High
          • Ocrevus's Product Profile in Relapsing Forms of MS
          • Ocrevus Information Requiring Additional Education
          • Initial Reaction to Ocrevus
          • Level of Interest in Learning More About Ocrevus
        • Impressions of Ocrevus
          • Surveyed Neurologists Have a Favorable Impression of Ocrevus's Risk/Benefit Profile in Relapsing Forms of MS
          • Unaided Advantages of Ocrevus for Relapsing Forms of MS
          • Unaided Disadvantages of Ocrevus for Relapsing Forms of MS
          • Statement Agreements About Ocrevus for Relapsing Forms of MS
          • Statement Agreements About Ocrevus for Relapsing Forms of MS (Mean)
          • Rating of Ocrevus's Risk-Benefit Balance for Relapsing Forms of MS
        • Prescriber and Nonprescriber Profiles
          • Early Prescribers of Ocrevus Have Larger Practices and Treat More Relapsing SP-MS Patients Than Nonprescribers
          • Differences Between Prescriber and Nonprescriber Profiles of Ocrevus
      • Ocrevus Trial and Use
        • Willingness to Prescribe Ocrevus
          • Willingness to Prescribe Ocrevus to Relapsing MS Patients
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in Relapsing Forms of MS
          • Mean Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in Relapsing Forms of MS
        • Number of Patients Currently Receiving Ocrevus
          • Nearly Half of Neurologists Surveyed Have Prescribed Ocrevus for Relapsing Forms of MS at One Month Postlaunch
          • Number of Relapsing MS Patients Prescribed Ocrevus
          • Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Mean Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Reasons for Discontinuing Ocrevus
          • Current Use of DMTs for RR-MS and Relapsing SP-MS Patients
          • Source of Business for Current Ocrevus-Treated Relapsing MS Patients
          • Source Therapy for Current Relapsing MS Patients Switched to Ocrevus
          • Number of Prior Therapies for Relapsing MS Patients Switched to Ocrevus
          • Reasons for Starting/Switching to Ocrevus in Relapsing Forms of MS
          • Relapsing MS Patient Inquiries About Ocrevus
          • Mean Number of Relapsing MS Patients Inquiring About Ocrevus
          • Percentage of Relapsing MS Patients Starting Ocrevus Following a Request
          • Ocrevus Follow-Up Visits in Relapsing MS
          • Ocrevus Treatment Response in Relapsing MS
          • Percentage of Relapsing MS Patients Ever Treated with Ocrevus Experiencing Select AEs
        • Reasons for Not Yet Prescribing Ocrevus
          • Short Time on the Market, Lack of Familiarity, and Safety Are Among the Key Constraints on Ocrevus Prescribing for Relapsing Forms of MS at One Month Postlaunch
          • Reasons for Not Yet Prescribing Ocrevus in Relapsing Forms of MS
          • Obstacles to Prescribing Ocrevus in Relapsing Forms of MS
        • Anticipated Ocrevus Use
          • Surveyed Neurologists Project Strong Uptake for Ocrevus in the Relapsing MS Market in the Next Six Months
          • Anticipated Timing for Ocrevus Prescribing for Relapsing Forms of MS Among Current Nonprescribers
          • Percentage of MS Patients Who Are Ocrevus Candidates, by Disease Classification
          • Percentage of Relapsing MS Patients Who Are Ocrevus Candidates, by Treatment Situation
          • Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Mean Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
          • Current and Anticipated Brand Allocation Among DMT-Treated SP-MS Patients
        • Ocrevus Performance on Key Attributes
          • One Month Postlaunch, Prescribers Express High Satisfaction with Ocrevus, and Many Perceive the Drug to Be Superior to Other MAbs on Safety
          • Prescribers' Overall Satisfaction with Ocrevus in Relapsing Forms of MS
          • Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Mean Ratings on Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Current Reimbursement Limitations on Ocrevus in the Context of Treating Relapsing Forms of MS
          • Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
          • Mean Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
      • Effectiveness of Face-to-Face Detailing for Ocrevus
        • Ocrevus Sales Representative Frequency and Reach
          • Approximately One-Third of Wave 1 Respondents Have Not Been Visited by an Ocrevus Representative
          • Sales Representative Detailing Reach
        • Satisfaction with Ocrevus Sales Representative
          • Mean Satisfaction with Ocrevus Sales Representative
        • Ocrevus Message Recall
          • Efficacy, Labeling, Safety, and Dosing Frequency Are Top of Mind for Neurologists After Recent Detailing of Ocrevus
          • Unaided Ocrevus Message Recall During Recent Detail
          • Aided Ocrevus Message Recall During Recent Detail
      • Methodology
        • Primary Market Research Methodology
        • State Location of Practice
        • U.S. Region of Practice
        • Practice Setting
        • Practice Location
        • Years in Practice Post-Residency
        • Patient Allocation by MS Disease Classification
        • Percentage of SP-MS Patients Who Suffer Superimposed Relapses
        • Current DMT Treatment Rate by MS Disease Classification
      • Appendix
        • Key Abbreviations Related to Multiple Sclerosis
        • Additional Primary Market Research
          • Reasons for Never Prescribing Ocrevus in Relapsing Forms of MS

    Author(s): Natalie Taylor, PhD; Jonathan Searles; Sarah Soucy

    Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.

    Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.

    Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

    Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.

    Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


    Related Reports

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details